{
    "Clinical Trial ID": "NCT00545688",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Trastuzumab+Docetaxel",
        "  Neoadjuvant (Pre-Operative) Treatment: Participants received trastuzumab IV infusion at a loading dose of 8 mg/kg on Day 1 of Cycle 1 (21-day cycle) followed by a maintenance dose of 6 mg/kg on Day 1 of Cycles 2-4 and docetaxel IV infusion at a starting dose of 75 mg/m^2 on Day 1 of Cycle 1 followed by 100 mg/m^2 on Day 1 of Cycles 2-4, if no dose limiting toxicity occurred.",
        "  Adjuvant (2-Week Post-Operative) Treatment: Participants received trastuzumab 6 mg/kg IV followed by FEC on Day 1 and every 3 weeks thereafter for three cycles (Cycles 5-7). Trastuzumab 6 mg/kg IV was continued every 3 weeks from Cycle 8 to Cycle 17.",
        "INTERVENTION 2: ",
        "  Trastuzumab+Pertuzumab+Docetaxel",
        "  Neoadjuvant (Pre-Operative) Treatment: Participants received trastuzumab IV infusion at a loading dose of 8 mg/kg and pertuzumab IV infusion at a loading dose of 840 mg on Day 1 of Cycle 1 (21-day cycle) followed by a maintenance dose of 6 mg/kg trastuzumab and 420 mg pertuzumab on Day 1 of Cycles 2-4. Docetaxel IV infusion was administered at a starting dose of 75 mg/m^2 on Day 1 of Cycle 1 followed by 100 mg/m^2 on Day 1 of Cycles 2-4, if no dose limiting toxicity occurred.",
        "  Adjuvant (2-Week Post-Operative) Treatment: Participants received trastuzumab 6 mg/kg IV followed by FEC on Day 1 and every 3 weeks thereafter for three cycles (Cycles 5-7). Trastuzumab 6 mg/kg IV was continued every 3 weeks from Cycle 8 to Cycle 17."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  female patients, >=18 years of age;",
        "  locally advanced, inflammatory or early stage invasive breast cancer;",
        "  HER2 positive (HER2+++ by IHC or FISH/CISH+).",
        "Exclusion Criteria:",
        "  metastatic disease (Stage IV) or bilateral breast cancer;",
        "  previous anticancer therapy or radiotherapy for any malignancy;",
        "  other malignancy, other than cancer in situ of the cervix, or basal cell cancer;",
        "  insulin-dependent diabetes;",
        "  clinically relevant cardiovascular disease."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Percentage of Participants Achieving Pathological Complete Response (pCR)",
        "  pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants with invalid/missing pCR assessments were defined as non-responders",
        "  Time frame: Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)",
        "Results 1: ",
        "  Arm/Group Title: Trastuzumab+Docetaxel",
        "  Arm/Group Description: Neoadjuvant (Pre-Operative) Treatment: Participants received trastuzumab IV infusion at a loading dose of 8 mg/kg on Day 1 of Cycle 1 (21-day cycle) followed by a maintenance dose of 6 mg/kg on Day 1 of Cycles 2-4 and docetaxel IV infusion at a starting dose of 75 mg/m^2 on Day 1 of Cycle 1 followed by 100 mg/m^2 on Day 1 of Cycles 2-4, if no dose limiting toxicity occurred.",
        "  Adjuvant (2-Week Post-Operative) Treatment: Participants received trastuzumab 6 mg/kg IV followed by FEC on Day 1 and every 3 weeks thereafter for three cycles (Cycles 5-7). Trastuzumab 6 mg/kg IV was continued every 3 weeks from Cycle 8 to Cycle 17.",
        "  Overall Number of Participants Analyzed: 107",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  29.0        (20.6 to 38.5)",
        "Results 2: ",
        "  Arm/Group Title: Trastuzumab+Pertuzumab+Docetaxel",
        "  Arm/Group Description: Neoadjuvant (Pre-Operative) Treatment: Participants received trastuzumab IV infusion at a loading dose of 8 mg/kg and pertuzumab IV infusion at a loading dose of 840 mg on Day 1 of Cycle 1 (21-day cycle) followed by a maintenance dose of 6 mg/kg trastuzumab and 420 mg pertuzumab on Day 1 of Cycles 2-4. Docetaxel IV infusion was administered at a starting dose of 75 mg/m^2 on Day 1 of Cycle 1 followed by 100 mg/m^2 on Day 1 of Cycles 2-4, if no dose limiting toxicity occurred.",
        "  Adjuvant (2-Week Post-Operative) Treatment: Participants received trastuzumab 6 mg/kg IV followed by FEC on Day 1 and every 3 weeks thereafter for three cycles (Cycles 5-7). Trastuzumab 6 mg/kg IV was continued every 3 weeks from Cycle 8 to Cycle 17.",
        "  Overall Number of Participants Analyzed: 107",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  45.8        (36.1 to 55.7)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 21/107 (19.63%)",
        "  Febrile neutropenia * 10/107 (9.35%)",
        "  Neutropenia * 1/107 (0.93%)",
        "  Left ventricular dysfunction * 0/107 (0.00%)",
        "  Angina pectoris * 0/107 (0.00%)",
        "  Cardiac failure congestive * 0/107 (0.00%)",
        "  Diarrhoea * 2/107 (1.87%)",
        "  Abdominal strangulated hernia * 0/107 (0.00%)",
        "  Duodenal ulcer haemorrhage * 0/107 (0.00%)",
        "  Pyrexia * 1/107 (0.93%)",
        "Adverse Events 2:",
        "  Total: 22/107 (20.56%)",
        "  Febrile neutropenia * 8/107 (7.48%)",
        "  Neutropenia * 6/107 (5.61%)",
        "  Left ventricular dysfunction * 3/107 (2.80%)",
        "  Angina pectoris * 1/107 (0.93%)",
        "  Cardiac failure congestive * 0/107 (0.00%)",
        "  Diarrhoea * 0/107 (0.00%)",
        "  Abdominal strangulated hernia * 1/107 (0.93%)",
        "  Duodenal ulcer haemorrhage * 0/107 (0.00%)",
        "  Pyrexia * 1/107 (0.93%)"
    ]
}